A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors - Trial NCT06328673
Access comprehensive clinical trial information for NCT06328673 through Pure Global AI's free database. This Phase 1 trial is sponsored by D2M Biotherapeutics Inc. and is currently Recruiting. The study focuses on Advanced Solid Tumor. Target enrollment is 160 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
D2M Biotherapeutics Inc.
Timeline & Enrollment
Phase 1
Mar 01, 2024
Mar 01, 2026
Primary Outcome
Number of treatment-emergent events (TEAEs) in Dose Escalation,RDEs or RP2Ds of DM919 alone and in combination with pembrolizumab
Summary
The goal of this clinical trial is to define a safe and effective dose of DM919 for
 participants with solid tumors
 
 The main questions it aims to answer are:
 
 What is the safe and effective dose of DM919 when used alone or in combination with
 pembrolizumab? What cancers can be treated effectively with DM919 alone or in combination
 with pembrolizumab??
 
 Participants will be asked to attend clinic and be given a intravenous infusion of DM919 or
 DM-919 in combination with pembrolizumab. They will have blood tests and other assessments to
 measure whether DM-919 will have the effect on tumors.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06328673
Non-Device Trial